The government is making a new push into the biotechnology sector by investing in a company that will focus on the development of a drug for treating AIDS.
The state-owned National Development Fund (NDF) will pump in US$20 million to help establish a biotech firm to be called TaiMed Biologics, Council for Economic Planning and Development Chairwoman Ho Mei-yueh (何美玥) told a press conference yesterday.
The move is one of a package of government measures designed to turn the nation's biotech industry into a trillion-dollar sector, following in the footsteps of the foundry and display industries.
PHOTO: CHEN TSE-MING, TAIPEI TIMES
Of the NT$30 billion (US$907 million) budget the government plans to invest in the biotech sector, the state fund has directly invested NT$8 billion in 12 biotech companies, Ho said, adding that the government could pump in more capital to fuel the industry's growth even after the budget is expended.
The new biotech company will be chaired by former vice premier Tsai Ying-wen (
David Ho told the press conference that, although it was impossible to know whether the NDF would see significant returns from its investment in TaiMed Biologics, this kind of investment is needed to stimulate the industry.
TaiMed Biologics purchased the patent for the drug TNX-355, which was developed by US-based Genentech Inc, and plans to complete development of the drug, which blocks HIV from entering human cells, in three years.
After launching TNX-355 on the global market, TaiMed Biologics will devote itself to developing flu and bird flu vaccines, he said.
If TaiMed Biologics later establishes a plant to manufacture drugs or other medical products, the NDF would also finance that, Ho Mei-yueh said.
Inviting private enterprises to jointly invest in TaiMed Biologics, the CEPD chairwoman said she had a shortlist of possible investors and would first approach Terry Gou (郭台銘), chairman of Hon Hai Precision Industry Co (鴻海精密).
On Sept. 4, Gou announced he would donate NT$15 billion to National Taiwan University to fund biomedical engineering projects and the construction of a hospital for treating cancer.
In June, Gou, who leads the world's largest contract maker of electronic components, reportedly said he would donate NT$100 billion to fund cancer research by scientists in Taiwan and China.
"I will brief him [to try to win] his support for the company [TaiMed Biologics]," Ho Mei-yueh said.
To encourage development of the biotechnology and pharmaceutical industry, the legislature in June passed tthe Biotech and New Pharmaceutical Development Statute (
The new law stipulates that 35 percent of company investment in R&D and personnel training in the two sectors is tax-deductible for the next five years.
If a firm's expenditure on R&D and personnel exceeds its average spending in the previous two years, 50 percent of the extra amount is tax-deductible.
In addition, employees in the industries who receive stock options do not need to pay income tax on their shares.
Government researchers who get permission from the institute where they are employed can also cooperate with private companies to develop new drugs, while researchers can work as consultants at private companies.
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday obtained the government’s approval to inject an additional US$10.26 billion to finance the construction of its second fab in Kumamoto, Japan, and a second fab in Arizona, using advanced process technologies. The Department of Investment Review approved TSMC’s investment applications on the basis that Taiwan remains a major technology and manufacturing hub for the chipmaker, which makes its most advanced chips at home, the company operates its research-and-development center here and the majority of its capacity remains in Taiwan. The latest capital injections — US$5.26 billion for its Japanese venture Japan Advanced Semiconductor Manufacturing
DIVERSIFYING: Following customers’ demand to improve supply chain resilience, ASE is looking for sites in the US, Japan and Mexico, a company executive said ASE Technology Holding Co (ASE, 日月光投控), the world’s biggest chip packaging and testing service provider, yesterday said it plans to launch a new high-end chip testing fab in the US next month to better serve its key customers based in North America, particularly California-based artificial intelligence (AI) customers. The new US testing facility would be operated by the firm’s subsidiary ISE Labs Inc, it said. ASE’s major customers, and high-ranking US officials and representatives from American Institute in Taiwan are to attend the fab’s opening ceremony on July 12, it said. ISE Labs last year acquired a 5,942m2 facility in San
Local companies believe that nearly a third of all job opportunities will vanish in 10 years due to the rise of artificial intelligence (AI), according to a survey released by online job bank yes123 on Tuesday. In the survey of 1,016 companies on the labor market’s third quarter outlook, the job bank focused in part on AI’s impact on workers and asked companies what percentage of jobs they felt would be lost to AI’s round-the-clock productivity and high-speed computing prowess. Respondents felt on average that 29.2 percent of job opportunities would be lost to AI over the next 10 years, but there
Taiwanese workers earned an average of NT$47,000 per month this year, but 40 percent are struggling financially and 18 percent plan to switch jobs within 12 months, two separate surveys showed yesterday. The amount equals a 5.4 percent increase from a year earlier to a decade high, 104 Job Bank (104人力銀行) said. The government is due to review the nation’s minimum wages. Employees at computer and consumer electronics manufacturers reported the highest average monthly wage of NT$60,000 a month, followed by semiconductor firms at NT$59,000, and vendors of shoe and textile products, along with software and Internet businesses at NT$55,000, 104 Job